Dangerous Drugs:
Menactra Vaccine
 Bookmark Bookmark RSS RSS
Adjust font size:

Menactra Meningococcal Vaccine

On October 20, 20056 , the Food and Drug Administration (FDA) along with the Centers for Disease Control and Prevention (CDC) updated a previous alert which announced that they are investigating the possibility of a link between Menactra Meningococcal Vaccine and Guillain Barre Syndrome (GBS). The investigation has found 15 confirmed cases of GBS in patients who had received the Menactra Meningococcal Vaccine manufactured by Sanofi Pasteur.

Guillian Barre Syndrome (GBS)

  • Guillian Barre Syndrome (GBS) is a neurological disorder that may require hospitalization.
  • Symptoms typically include increased weakening in the legs and arms. In severe cases, paralysis may occur.
  • Although most patients with GBS recover after a few weeks, some people suffer with these symptoms for months or years.
  • In the most serious cases of paralysis, a patient may die from the disease.

Menactra Meningococcal Vaccine

  • The Menactra vaccine was approved in January of 2005 to protect against bacterial meningitis.
  • The vaccine is typically given to adolescents before high-school entry. It is also recommended for first-year college students living in dormitories.
  • The FDA reports that more than 2.5 million doses of Menactra Meningococcal Vaccine have been administered in the U.S.

The 15 cases reported to the FDA that could possibly link GBS to the meningitis vaccine occurred in individuals who were between the ages of 11-19. Two additional cases were confirmed in adults over the age of 20.

These individuals developed symptoms within six weeks of receiving Menactra vaccine. All have recovered or are in the process of recovery.

These cases suggest a small increase risk of GBS following immunization with Menactra. However, officials cannot say with certainty that the reports of GBS were caused by the vaccine. Currently, there are no changes in recommendations for vaccination.

Because many vaccine adverse effects are not reported, the FDA suspects that there may be additional cases.

Note - Do not change medications without first consulting your doctor.
Free Case Evaluation
Free Case Evaluation
Free Case Evaluation

If you or someone you know has received the Menactra Vaccine and have been diagnosed with GBS, please fill out the form below for a free evaluation of your case or call us at 1-800-275-0192.

We can help you understand your rights and options, and seek compensation for your injuries.

The information you provide will only be used in accordance with our terms and conditions. By submitting this form, you certify that you agree to our terms and conditions and want us to contact you regarding your inquiry.

* denotes required fields
Title
First Name
Middle Initial
Last Name
Address
Address Cont.
City
State
Zip Code
Phone Number (day)
Phone Number (eve)
E-mail
If this inquiry is not for yourself, please tell us the name of the person.
Title
First Name
Middle Initial
Last Name
What is this person's relationship to you?
Injured's date of birth:  [None] Select a Date Delete the Date
Did you or a loved one take Menactra?
If yes, which city and state was the medication prescribed in?
What were the dates of use?
Did you suffer an injury as a result of taking the medication? Yes No
What injury occurred?
Do you/Injured currently have an attorney helping you with this matter? Yes No
Please briefly describe your legal issues and needs.
In This Section:
Overview